{"result": {"id": "chatcmpl-BU4GxS2gd6KDUuWbPA0QV3TBiUxRF", "choices": [{"finish_reason": "stop", "index": 0, "logprobs": null, "message": {"content": "(\"entity\"<|>AUTologous BONE MARROW TRANSPLANT TREATMENT<|>EVENT<|>Continuation of the Autologous Bone Marrow Transplant Treatment for Multiple Myeloma involves several stages including stem-cell mobilisation and post-transplant monitoring.)\n##\n(\"entity\"<|>MULTIPLE MYELOMA<|>BENEFIT<|>Multiple Myeloma is a type of cancer for which the Autologous Bone Marrow Transplant Treatment is being provided.)\n##\n(\"entity\"<|>PROTON BEAM THERAPY<|>EVENT<|>Proton Beam Therapy is a treatment option for cancer that can be administered as an inpatient, day surgery, or outpatient procedure.)\n##\n(\"entity\"<|>REGISTERED MEDICAL PRACTITIONER<|>PERSON<|>A healthcare professional who is authorized to treat patients and administer therapies such as Proton Beam Therapy.)\n##\n(\"entity\"<|>HOSPITAL<|>ORGANIZATION<|>A facility where patients receive medical treatment, including outpatient procedures for cancer therapies.)\n##\n(\"entity\"<|>MEDISAVE/MEDISHIELD LIFE<|>ORGANIZATION<|>Accredited cancer treatment centres that provide coverage for treatments like Proton Beam Therapy.)\n##\n(\"relationship\"<|>AUTologous BONE MARROW TRANSPLANT TREATMENT<|>MULTIPLE MYELOMA<|>The Autologous Bone Marrow Transplant Treatment is specifically designed to treat Multiple Myeloma.<|>8)\n##\n(\"relationship\"<|>PROTON BEAM THERAPY<|>MULTIPLE MYELOMA<|>Proton Beam Therapy is a treatment option available for patients with Multiple Myeloma.<|>7)\n##\n(\"relationship\"<|>REGISTERED MEDICAL PRACTITIONER<|>HOSPITAL<|>Registered Medical Practitioners work in hospitals to provide treatments like Proton Beam Therapy.<|>6)\n##\n(\"relationship\"<|>HOSPITAL<|>MEDISAVE/MEDISHIELD LIFE<|>Hospitals are accredited by MediSave/MediShield Life to provide certain cancer treatments.<|>5)\n<|COMPLETE|>", "refusal": null, "role": "assistant", "annotations": [], "audio": null, "function_call": null, "tool_calls": null}}], "created": 1746505963, "model": "gpt-4o-mini-2024-07-18", "object": "chat.completion", "service_tier": "default", "system_fingerprint": "fp_96c46af214", "usage": {"completion_tokens": 454, "prompt_tokens": 2238, "total_tokens": 2692, "completion_tokens_details": {"accepted_prediction_tokens": 0, "audio_tokens": 0, "reasoning_tokens": 0, "rejected_prediction_tokens": 0}, "prompt_tokens_details": {"audio_tokens": 0, "cached_tokens": 1664}}}, "input": {"messages": [{"content": "\n-Goal-\nGiven a text document that is potentially relevant to this activity and a list of entity types, identify all entities of those types from the text and all relationships among the identified entities.\n \n-Steps-\n1. Identify all entities. For each identified entity, extract the following information:\n- entity_name: Name of the entity, capitalized\n- entity_type: One of the following types: [organization,person,benefit,date,event,location]\n- entity_description: Comprehensive description of the entity's attributes and activities\nFormat each entity as (\"entity\"<|><entity_name><|><entity_type><|><entity_description>)\n \n2. From the entities identified in step 1, identify all pairs of (source_entity, target_entity) that are *clearly related* to each other.\nFor each pair of related entities, extract the following information:\n- source_entity: name of the source entity, as identified in step 1\n- target_entity: name of the target entity, as identified in step 1\n- relationship_description: explanation as to why you think the source entity and the target entity are related to each other\n- relationship_strength: a numeric score indicating strength of the relationship between the source entity and target entity\n Format each relationship as (\"relationship\"<|><source_entity><|><target_entity><|><relationship_description><|><relationship_strength>)\n \n3. Return output in English as a single list of all the entities and relationships identified in steps 1 and 2. Use **##** as the list delimiter.\n \n4. When finished, output <|COMPLETE|>\n \n######################\n-Examples-\n######################\nExample 1:\nEntity_types: ORGANIZATION,PERSON\nText:\nThe Verdantis's Central Institution is scheduled to meet on Monday and Thursday, with the institution planning to release its latest policy decision on Thursday at 1:30 p.m. PDT, followed by a press conference where Central Institution Chair Martin Smith will take questions. Investors expect the Market Strategy Committee to hold its benchmark interest rate steady in a range of 3.5%-3.75%.\n######################\nOutput:\n(\"entity\"<|>CENTRAL INSTITUTION<|>ORGANIZATION<|>The Central Institution is the Federal Reserve of Verdantis, which is setting interest rates on Monday and Thursday)\n##\n(\"entity\"<|>MARTIN SMITH<|>PERSON<|>Martin Smith is the chair of the Central Institution)\n##\n(\"entity\"<|>MARKET STRATEGY COMMITTEE<|>ORGANIZATION<|>The Central Institution committee makes key decisions about interest rates and the growth of Verdantis's money supply)\n##\n(\"relationship\"<|>MARTIN SMITH<|>CENTRAL INSTITUTION<|>Martin Smith is the Chair of the Central Institution and will answer questions at a press conference<|>9)\n<|COMPLETE|>\n\n######################\nExample 2:\nEntity_types: ORGANIZATION\nText:\nTechGlobal's (TG) stock skyrocketed in its opening day on the Global Exchange Thursday. But IPO experts warn that the semiconductor corporation's debut on the public markets isn't indicative of how other newly listed companies may perform.\n\nTechGlobal, a formerly public company, was taken private by Vision Holdings in 2014. The well-established chip designer says it powers 85% of premium smartphones.\n######################\nOutput:\n(\"entity\"<|>TECHGLOBAL<|>ORGANIZATION<|>TechGlobal is a stock now listed on the Global Exchange which powers 85% of premium smartphones)\n##\n(\"entity\"<|>VISION HOLDINGS<|>ORGANIZATION<|>Vision Holdings is a firm that previously owned TechGlobal)\n##\n(\"relationship\"<|>TECHGLOBAL<|>VISION HOLDINGS<|>Vision Holdings formerly owned TechGlobal from 2014 until present<|>5)\n<|COMPLETE|>\n\n######################\nExample 3:\nEntity_types: ORGANIZATION,GEO,PERSON\nText:\nFive Aurelians jailed for 8 years in Firuzabad and widely regarded as hostages are on their way home to Aurelia.\n\nThe swap orchestrated by Quintara was finalized when $8bn of Firuzi funds were transferred to financial institutions in Krohaara, the capital of Quintara.\n\nThe exchange initiated in Firuzabad's capital, Tiruzia, led to the four men and one woman, who are also Firuzi nationals, boarding a chartered flight to Krohaara.\n\nThey were welcomed by senior Aurelian officials and are now on their way to Aurelia's capital, Cashion.\n\nThe Aurelians include 39-year-old businessman Samuel Namara, who has been held in Tiruzia's Alhamia Prison, as well as journalist Durke Bataglani, 59, and environmentalist Meggie Tazbah, 53, who also holds Bratinas nationality.\n######################\nOutput:\n(\"entity\"<|>FIRUZABAD<|>GEO<|>Firuzabad held Aurelians as hostages)\n##\n(\"entity\"<|>AURELIA<|>GEO<|>Country seeking to release hostages)\n##\n(\"entity\"<|>QUINTARA<|>GEO<|>Country that negotiated a swap of money in exchange for hostages)\n##\n##\n(\"entity\"<|>TIRUZIA<|>GEO<|>Capital of Firuzabad where the Aurelians were being held)\n##\n(\"entity\"<|>KROHAARA<|>GEO<|>Capital city in Quintara)\n##\n(\"entity\"<|>CASHION<|>GEO<|>Capital city in Aurelia)\n##\n(\"entity\"<|>SAMUEL NAMARA<|>PERSON<|>Aurelian who spent time in Tiruzia's Alhamia Prison)\n##\n(\"entity\"<|>ALHAMIA PRISON<|>GEO<|>Prison in Tiruzia)\n##\n(\"entity\"<|>DURKE BATAGLANI<|>PERSON<|>Aurelian journalist who was held hostage)\n##\n(\"entity\"<|>MEGGIE TAZBAH<|>PERSON<|>Bratinas national and environmentalist who was held hostage)\n##\n(\"relationship\"<|>FIRUZABAD<|>AURELIA<|>Firuzabad negotiated a hostage exchange with Aurelia<|>2)\n##\n(\"relationship\"<|>QUINTARA<|>AURELIA<|>Quintara brokered the hostage exchange between Firuzabad and Aurelia<|>2)\n##\n(\"relationship\"<|>QUINTARA<|>FIRUZABAD<|>Quintara brokered the hostage exchange between Firuzabad and Aurelia<|>2)\n##\n(\"relationship\"<|>SAMUEL NAMARA<|>ALHAMIA PRISON<|>Samuel Namara was a prisoner at Alhamia prison<|>8)\n##\n(\"relationship\"<|>SAMUEL NAMARA<|>MEGGIE TAZBAH<|>Samuel Namara and Meggie Tazbah were exchanged in the same hostage release<|>2)\n##\n(\"relationship\"<|>SAMUEL NAMARA<|>DURKE BATAGLANI<|>Samuel Namara and Durke Bataglani were exchanged in the same hostage release<|>2)\n##\n(\"relationship\"<|>MEGGIE TAZBAH<|>DURKE BATAGLANI<|>Meggie Tazbah and Durke Bataglani were exchanged in the same hostage release<|>2)\n##\n(\"relationship\"<|>SAMUEL NAMARA<|>FIRUZABAD<|>Samuel Namara was a hostage in Firuzabad<|>2)\n##\n(\"relationship\"<|>MEGGIE TAZBAH<|>FIRUZABAD<|>Meggie Tazbah was a hostage in Firuzabad<|>2)\n##\n(\"relationship\"<|>DURKE BATAGLANI<|>FIRUZABAD<|>Durke Bataglani was a hostage in Firuzabad<|>2)\n<|COMPLETE|>\n\n######################\n-Real Data-\n######################\nEntity_types: organization,person,benefit,date,event,location\nText: twice, i.e. on two separate life events, \nprovided:\n- all premiums due under this policy are paid; \n- the life assured is under 45 years old;\n- this policy has not terminated, for any reason;\n- no claim has been made under this policy or PRUExtra policy (if any); \n- the total sum assured of the new policies does not exceed the amount set out in the Benefits\nSchedule; and\n- the new policy is purchased within 3 months from the date of the relevant life event.\n1.4.6.7 What do we pay for Continuation of the Autologous Bone Marrow Transplant \nTreatment for Multiple Myeloma?\nWe reimburse for the Reasonable and Customary Expenses incurred, up to the limits as set out in the \nBenefits Schedule, if the life assured undergoes Medically Necessary Continuation of the Autologous \nBone Marrow Transplant Treatment for Multiple Myeloma for the following stages of the treatment:\n- Stem-cell mobilisation \n- Harvesting healthy stem cells\n- Pre-transplant workup\n- Use of high dosage chemotherapeutic drugs to destroy cancerous cells\n- Engraftment of healthy stem cells\n- Post-transplant monitoring \nWe will pay for all treatment costs, including consultation, clinical and lab investigations, consumables \nand drugs needed for the Continuation of Autologous Bone Marrow Transplant Treatment for Multiple \nMyeloma in the outpatient setting.\nThis applies strictly to treatment in the outpatient setting only. If the life assured requires certain phases \nof bone marrow transplant in the inpatient setting, these treatments will be covered under the \nprevailing inpatient limits.\nThis benefit is subject to the Deductible, Co-insurance and Pro-ration.\nWe will not pay for any pre or post-hospitalisation expenses incurred in relation to the Autologous \nBone Marrow Transplant Treatment for Multiple Myeloma. 1.4.6.8 What do we pay for Inpatient and Outpatient Proton Beam Therapy?\nWe reimburse for the Reasonable and Customary Expenses incurred, up to the limits as set out in the \nBenefits Schedule, when the life assured undergoes Proton Beam Therapy treatment as an Inpatient, \nday surgery or Outpatient procedure, treated by a Registered Medical Practitioner in a Hospital or \nMediSave/MediShield Life accredited cancer treatment centres. \nThis benefit is subject to the Deduct\n######################\nOutput:", "role": "user"}], "parameters": {"model": "gpt-4o-mini", "frequency_penalty": 0.0, "max_tokens": null, "n": 1, "presence_penalty": 0.0, "temperature": 0.0, "top_p": 1.0}}}